Early Phase Manufacture And Process Development

Oxford Biomedica (OXB) has established the leading serum free, single use, commercial process for the manufacture of cGMP lentiviral vectors. We offer our partners the opportunity to leverage that experience and knowledge to achieve rapid progress, from product development to released cGMP batch.

Speed to clinical studies is highly desirable in drug development, and in gene therapy this can be challenging. We offer rapid entry to clinical trials through the application of a tried and tested process, allied to deep knowledge of lentiviral vector process development, enabling our partners to save time and money.